ELRANATAMAB

UNII:	L0HR9A577V
Formula:
Preferred Substance Name:	ELRANATAMAB
GSRS Full Record:	L0HR9A577V i

2408850-14-4
ANTI-CD3/ANTI-BCMA BISPECIFIC MONOCLONAL ANTIBODY PF-06863135
B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
ELRANATAMAB [INN]
ELRANATAMAB [USAN]
ELRANATAMAB [WHO-DD]
ELRANATAMAB BCMM [WHO-DD]
ELRANATAMAB-BCMM
ELREXFIO
IMMUNOGLOBULIN G2 (224-ARGININE,265-ALANINE,330-SERINE,331-SERINE), ANTI-(HUMAN CD3 ANTIGEN .EPSILON.-CHAIN) (HUMAN-MUS MUSCULUS MONOCLONAL PF-06863059 .GAMMA.2-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL PF-06863059 .KAPPA.-CHAIN, (223->217')(227->221')(230->224')-TRIS(DISULFIDE) WITH IMMUNOGLOBULIN G2 (218-GLUTAMIC ACID,259-ALANINE,324-SERINE,325-SERINE) ANTI-(HUMAN B-CELL MATURATION ANTIGEN) (HUMAN MONOCLONAL PF-06863058 .GAMMA.2-CHAIN) DISULFIDE WITH HUMAN MONOCLONAL PF-06863058 .KAPPA.-CHAIN
PF-06863135
RN613
RN-613

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

ELRANATAMAB

Synonyms and Mappings

Resources